On her website, she is unabashedly gushing with hope about Burzynski’s treatment. Days before she left, she and her boyfriend Jedd recorded a touching and heartfelt thank you to people who had supported her through her journey and brave fight, raising money and pulling for her. They were preparing to get a catheter inserted into her chest, presumably for the ANP treatment:
Patients are generally not expected to pay for a treatment in development. This is because the person developing the treatment intends to market the treatment broadly. The trial is part of the investment. Burzynski adopts none of the risks that any other researcher adopts. Charging terminal patients UP FRONT to me seems to me to be a clear indication that he has no intention of seeing his product gain approval that would allow it to be marketed. According to the article above, “The clinic has currently been approved for Phase III Clinical Trial for Antineoplastons treatment and Rachael M.’s brain tumor met the criteria to be accepted as a patient in the trial.”
But when you go to clinicaltrials.gov, the only open Phase III clinical trial we see is NOT YET RECRUITING:
It’s clear from the remembrances and comments that she was well loved and will be missed.
For patients interested in enrolling in or learning about legitimate clinical trials, please visit the NIH clinical trial fact sheet:
Donations in Rachael’s name may be made to:
Rachael M. Scholarship Fund, PO Box 131 Danvers MA, 01923
According to the family: “Funds will be used to establish a yearly scholarship in Rae’s name to a student that has the same courage, positive outlook and determination in life that Rachael had.”